Eyevensys

Platforms for long acting non-viral gene therapy for ocular diseases.

Launch date

2008

Employees

Market cap

Enterprise valuation

$150m (Public information from Aug 2021)

Company register number 509397832

Paris Île-de-France (HQ)

Revenues, earnings & profits over time

EUR	2015	2016	2017	2018	2019	2020	2021
EBITDA	(2.9m)	(2.2m)	(3.4m)	(5.5m)	-	(6.1m)	(10.8m)
Profit	(1.8m)	(1.8m)	(2.6m)	(4.9m)	(7.8m)	(4.7m)	(9.5m)

Source: Dealroom estimates

Date	Investors	Amount	Round
-	Sofimac Innovation Pureos Bioventures	N/A	-
Jan 2008*	INSERM Université Paris Cité	N/A	Spinout
Apr 2013	Boehringer Ingelheim Venture Fund	N/A	Early VC
Jun 2015	Inserm Transfert Initiative Karista	N/A	Seed
Sep 2016*	Pontifax Funds	€9.0m	Series A
Jan 2020	Bpifrance Inserm Transfert Initiative Boehringer Ingelheim Venture Fund Quark Venture Global health sciences venture fund Karista	$30.0m	Series B
Aug 2021	Korea Investment Partners	$12.0m Valuation: $150m -22.3x EV/LTM EBITDA	Series B
Total Funding		$51.9m

Tech stackLearn more about the technologies and tools that this company uses.

Financials